乳腺癌居女性恶性肿瘤发病率的第1位,人类表皮生长因子受体2 (human epiderma growth factor receptor-2, HER-2)过表达型的患者病情进展迅速,易发生淋巴结、骨骼、脑等多器官转移。本文回顾性分析1例临床分期为T4N1M0的HER-2过表达型...乳腺癌居女性恶性肿瘤发病率的第1位,人类表皮生长因子受体2 (human epiderma growth factor receptor-2, HER-2)过表达型的患者病情进展迅速,易发生淋巴结、骨骼、脑等多器官转移。本文回顾性分析1例临床分期为T4N1M0的HER-2过表达型乳腺癌患者,新辅助化疗、靶向治疗后行乳腺癌根治术,术后病理分期为ypTisN0M0,后行化疗、靶向及放疗,观察其疗效,并回顾分析相关文献。该患者随诊至今暂无转移复发。Breast cancer ranks the first place in the incidence of female malignant tumors. Patients with HER-2 over-expressing breast cancer progress rapidly, and lymph node, bone, brain and other organs are prone to metastasis. A case of HER-2 over-expressing breast cancer with clinical stage of T4N1M0 was retrospectively analyzed. After neoadjuvant chemotherapy and targeted therapy, modified radical mastectomy was performed. The pathological stage was ypTisN0M0, and then followed by chemotherapy, targeted therapy and radiotherapy. The patient has no metastasis or recurrence.展开更多
文摘乳腺癌居女性恶性肿瘤发病率的第1位,人类表皮生长因子受体2 (human epiderma growth factor receptor-2, HER-2)过表达型的患者病情进展迅速,易发生淋巴结、骨骼、脑等多器官转移。本文回顾性分析1例临床分期为T4N1M0的HER-2过表达型乳腺癌患者,新辅助化疗、靶向治疗后行乳腺癌根治术,术后病理分期为ypTisN0M0,后行化疗、靶向及放疗,观察其疗效,并回顾分析相关文献。该患者随诊至今暂无转移复发。Breast cancer ranks the first place in the incidence of female malignant tumors. Patients with HER-2 over-expressing breast cancer progress rapidly, and lymph node, bone, brain and other organs are prone to metastasis. A case of HER-2 over-expressing breast cancer with clinical stage of T4N1M0 was retrospectively analyzed. After neoadjuvant chemotherapy and targeted therapy, modified radical mastectomy was performed. The pathological stage was ypTisN0M0, and then followed by chemotherapy, targeted therapy and radiotherapy. The patient has no metastasis or recurrence.
